欧洲青光眼患病率及至2050年的预测:欧洲眼流行病学联盟的研究结果
PURPOSE: To provide updated glaucoma prevalence estimates and to quantify the current and future burden of disease in Europe. DESIGN: Two-stage, individual participant data meta-analysis.…
要点
- 欧洲≥40岁成人年龄标化青光眼患病率为2.99%(95%CI 2.86%-3.12%)。
- 56.4%的青光眼病例此前未确诊,<55岁人群中未检出比例>80%。
核心结论
- 欧洲青光眼当前和未来负担可能远高于既往估计,普通人群中相当比例疾病未被检出。
- 这一发现可能对其他仅基于已发表聚合水平数据估算患病人数的年龄相关疾病具有更广泛意义。
研究设计与样本
- 两阶段个体参与者数据荟萃分析,纳入14项1991-2020年人群研究共55415名≥40岁成人(平均年龄65.6岁,53.9%女性),病例确定基于直接眼科检查。
主要发现
- 2021名参与者(3.65%)诊断为青光眼,年龄标化欧洲患病率为2.99%(95%CI 2.86%-3.12%)。
- 年龄较大与患病率较高相关(每增加5岁OR 1.32;95%CI 1.29-1.36;P < 0.001),男性与患病率较高相关(OR 1.18;95%CI 1.08-1.30;P < 0.001)。
- 尽管患病率估计存在地区和诊断差异,未发现时间趋势。
- 56.4%的病例此前未确诊,年轻参与者中未检出比例更高,<55岁人群中>80%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide updated glaucoma prevalence estimates and to quantify the current and future burden of disease in Europe. DESIGN: Two-stage, individual participant data meta-analysis. PARTICIPANTS: We included 55 415 adults ≥40 years of age (mean age, 65.6 years; 53.9% women) from 14 population-based studies (1991-2020) with case ascertainment based on direct ophthalmic examination. METHODS: Within each study, age- and sex-stratified glaucoma prevalence was calculated, before pooling results using random-effects meta-analysis and performing age standardization. Meta-regression and subgroup analyses were used to assess for temporal trends and to investigate heterogeneity across clinically relevant subgroups. Estimates were applied to European population projections to predict the number of individuals with glaucoma. MAIN OUTCOME MEASURES: Age-standardized prevalence (European Standard Population, 2013) of total and previously undiagnosed glaucoma for individuals ≥40 years of age and annual projected number of glaucoma cases (UN World Population Prospects, 2022) in Europe to 2050. RESULTS: Overall, 2021 participants (3.65%) received a diagnosis of glaucoma with an age-standardized European prevalence of 2.99% (95% confidence interval [CI], 2.86%-3.12%). Older age (odds ratio [OR], 1.32 per 5-year increase; 95% CI, 1.29-1.36; P < 0.001) and male sex (OR, 1.18; 95% CI, 1.08-1.30; P < 0.001) were associated with higher prevalence. Despite regional and diagnostic differences in prevalence estimates, no temporal trend was identified. More than half (56.4%) of cases were undiagnosed previously, with a higher proportion of undetected disease in younger participants, including >80% in those <55 years of age. We estimate a current burden of 12.3 million individuals with glaucoma in Europe, including 6.9 million individuals with undiagnosed disease. This burden is projected to grow by >1 million people by 2050 because of changing population age structure, with a preponderance of primary open-angle glaucoma. CONCLUSIONS: The current and future burden of glaucoma in Europe may be substantially higher than previously estimated, with a considerable proportion of disease in the general population remaining undetected. This may have broader implications for other age-related conditions in which the number of affected individuals is based solely on published aggregate-level data. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Stuart KV, de Vries VA, Schuster AK, et al. Prevalence of Glaucoma in Europe and Projections to 2050: Findings from the European Eye Epidemiology Consortium. Ophthalmology. 2025. PMID: 40499787. doi:10.1016/j.ophtha.2025.06.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。